Download pdf
Molecular mechanism and targeted therapy of breast cancer
- 1 Hangzhou NO.14 High School
* Author to whom correspondence should be addressed.
Abstract
A common malignant tumor that poses a major threat to women’s health is breast cancer (BC). BC is mostly caused by aberrant cells in the breast and is primarily influenced by hormone levels, environmental factors, and genetics. Currently, the tumor’s features and stage determine the course of treatment for patients who have been diagnosed. Surgical resection, radiation therapy, chemotherapy, and targeted therapy are often used forms of treatment. Because of its few side effects and excellent treatment efficacy, targeted therapy has gained popularity in the fight against cancer. The goal of this article is to investigate potential future development trends in the field of BC by focusing on the pathophysiology, diagnosis, and therapy of the disease. This paper indicates that while new objectives for BC have made considerable strides in recent years, The biggest obstacles to a cure for BC are metastasis and recurrence, making the prognosis still quite difficult. To increase the survival rates of BC patients, more research and the creation of novel treatments are therefore essential.
Keywords
Breast cancer, mechanism, targeted therapy
[1]. Beltran H & Demichelis F 2021 Therapy considerations in neuroendocrine prostate cancer: what next? Endocrine-Related Cancer 28(8) T67
[2]. Zhang G Q Chen J L Luo Y Mathur M B Anagnostis P Nurmatov U & Nwaru B I 2021 Menopausal hormone therapy and women’s health: An umbrella review PLoS Med 18(8) e1003731
[3]. Prasanna Ekambaram Jia-Ying (Lloyd) Lee et al 2018 The CARMA3–Bcl10–MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor–Positive Breast Cancer Cancer Res 1 March 78 (5) 1225–1240
[4]. Hou P Li L Chen Fet al 2018 PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial–mesenchymal transition in breast cancer Cancer Res78(2) 387-398
[5]. El-Shennawy L Dubrovskyi O Kastrati I et al 2018 Coactivation of estrogen receptor and IKKβ induces a dormant metastatic phenotype in ER-positive breast cancer Cancer Res 78(4) 974-984
[6]. Ludwik K A McDonald O G et al 2018 ERα-mediated nuclear sequestration of RSK2 is required for ER+ breast cancer tumorigenesis Cancer Res 78(8) 2014-2025
[7]. Campbell T M Castro M A et al 2018 ERα binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast cancer Cancer Res 78(2) 410-421
[8]. Ren D Zhu X Kong Ret al 2018 Targeting brain-adaptive cancer stem cells prohibits brain metastatic colonization of triple-negative breast cancer Cancer Res 78(8) 2052-2064
[9]. Suyama K Yao J Liang Het al 2018 An Akt3 splice variant lacking the serine 472 phosphorylation site promotes apoptosis and suppresses mammary tumorigenesis Cancer Res 78(1) 103-114
[10]. Saha M Kumar S Bukhari Set al 2018 AMPK–Akt double-negative feedback loop in breast cancer cells regulates their adaptation to matrix deprivation Cancer Res 78(6) 1497-1510
Cite this article
Yao,X. (2024). Molecular mechanism and targeted therapy of breast cancer. Theoretical and Natural Science,32,293-297.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).